Maze Therapeutics Inc. (MAZE)
The price, the headline numbers and the latest news, in one place.
Maze Therapeutics Inc. (MAZE) Stock Price, Analysis & Data
| Bid | 19.91 |
| Market Cap | 1.52B |
| Revenue (ttm) | 20M |
| Net Income (ttm) | -133.59M |
| n/a | |
| -2.44 | |
| n/a | |
| -8.64 | |
| P/B (ttm) | 3.36 |
| P/S (ttm) | 76.21 |
| Earnings Date | Nov 5, 2026 |
| Ask | 35.55 |
| Volume | 250,248 |
| Avg. Volume (20D) | 549,138 |
| Open | 28.46 |
| Previous Close | 28.60 |
| Day's Range | 27.31 - 28.46 |
| 52-Week Range | 14.16 - 53.65 |
| Analyst | Strong Buy |
| Price Target | 55 (100.44%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About MAZE
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready c...
Financial Performance
In 2025, Maze Therapeutics's revenue was 0, a decrease of -100% compared to the previous year's 167.5M. Earnings were -131.12M, a decrease of -351.04%.
Financial StatementsAnalyst Forecast
According to 11 analyst ratings, the average rating for MAZE stock is "Strong Buy". The 12-month stock price forecast is 55, which is upside of 100.44% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $20M misses estimates by $0, with Infinity% YoY growth.
- EPS of -0.76 misses estimates by -0.06, with 33.91% YoY growth.
Analysts project revenue of ... Upgrade
2 months ago · Simply Wall St.
Maze Therapeutics Phase 2 Kidney Data Sparks Questions On Upside And RiskMaze Therapeutics (NasdaqGM:MAZE) reported positive topline results from its Phase 2 HORIZON trial of MZE829 in APOL1-mediated kidney disease. The company plans to advance MZE829 into a pivotal trial ...
